In 518 patients with coronary artery disease in China, a sirolimus-eluting iron bioresorbable scaffold (IBS) was noninferior to CoCr everolimus-eluting stents for 2-year late lumen loss (0.28 vs 0.23 mm). Target lesion failure: 7.4% vs 5.4% (NS); restenosis was higher with IBS.
RCTn = 518
Gao et al. Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II)